{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:15:22Z","timestamp":1782663322564,"version":"3.54.5"},"reference-count":163,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JPM"],"abstract":"<jats:p>Psychedelic compounds are gaining renewed attention across disciplines for their profound psychological and neurobiological effects. Emerging research highlights their efficacy in treating mood disorders, PTSD, and addiction by enhancing neuroplasticity and disrupting maladaptive cognitive patterns. From a psychological standpoint, psychedelics facilitate introspection, emotional processing, and therapeutic breakthroughs. Neuroscientific findings reveal altered brain network dynamics, while anthropological and philosophical perspectives contextualize their cultural and existential significance. In medicine, they offer novel interventions for chronic pain and palliative care. The present review article underscores the need for rigorous, ethically grounded research to explore psychedelics\u2019 potential in reshaping mental health paradigms and cognitive science from a multidisciplinary perspective.<\/jats:p>","DOI":"10.3390\/jpm15100450","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:59:46Z","timestamp":1759150786000},"page":"450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-0678","authenticated-orcid":false,"given":"Kerem Kemal","family":"Soylemez","sequence":"first","affiliation":[{"name":"School of Psychology, Regent\u2019s University London, London NW1 4NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Marie","family":"de Boo","sequence":"additional","affiliation":[{"name":"School of Psychology, Regent\u2019s University London, London NW1 4NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysil","family":"Susuzlu","sequence":"additional","affiliation":[{"name":"School of Psychology, Regent\u2019s University London, London NW1 4NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7035-0255","authenticated-orcid":false,"given":"Joanne","family":"Lusher","sequence":"additional","affiliation":[{"name":"School of Psychology, Regent\u2019s University London, London NW1 4NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.24875\/RIC.23000108","article-title":"The resurgence of hallucinogen drugs in clinical research","volume":"75","author":"Cruz","year":"2023","journal-title":"Rev. Investig. Cl\u00ednica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/02791072.2019.1581961","article-title":"Beyond LSD: A broader psychedelic zeitgeist during the early to mid-20th century","volume":"51","author":"Aday","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1556\/2054.2019.018","article-title":"Making psychedelics into medicines: The politics and paradoxes of medicalization","volume":"4","author":"Noorani","year":"2020","journal-title":"J. Psychedelic Stud."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sessa, B. (2016). The history of psychedelics in medicine. Handb. Psychoaktive Subst., 1\u201326.","DOI":"10.1007\/978-3-642-55214-4_96-1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5694\/mja2.52281","article-title":"The mental health crisis needs more than increased investment in the mental health system","volume":"220","author":"Suetani","year":"2024","journal-title":"Med. J. Aust."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/cpt1974164625","article-title":"The biochemical pharmacology of abused drugs","volume":"16","author":"Caldwell","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pbr.2018.09.013","article-title":"An introduction to psychedelic neuroscience","volume":"242","author":"Calvey","year":"2018","journal-title":"Prog. Brain Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/0022167882223004","article-title":"Psychedelics and psychological well-being","volume":"22","author":"Walsh","year":"1982","journal-title":"J. Humanist. Psychol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Falcon, J. (2025). Anthropology of Psychedelics. Anthropol. Conscious., e70002.","DOI":"10.1111\/anoc.70002"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1556\/2054.2021.00191","article-title":"Philosophy and classic psychedelics: A review of some emerging themes","volume":"5","author":"Letheby","year":"2022","journal-title":"J. Psychedelic Stud."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Husain, M.I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J.D., Blumberger, D.M., Mulsant, B.H., and Castle, D.J. (2023). Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.1076459"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","article-title":"Default mode network modulation by psychedelics: A systematic review","volume":"26","author":"Gattuso","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/npp.2015.342","article-title":"Increased default mode network connectivity in individuals at high familial risk for depression","volume":"41","author":"Posner","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/hbm.22833","article-title":"Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin","volume":"36","author":"Lebedev","year":"2015","journal-title":"Hum. Brain Mapp."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"De Vos, C.M., Mason, N.L., and Kuypers, K.P. (2021). Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.724606"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/s41380-023-02271-0","article-title":"Neuroimaging in psychedelic drug development: Past, present, and future","volume":"28","author":"Wall","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","article-title":"The molecular mechanism of \u201cecstasy\u201d [3,4-methylenedioxy-methamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release","volume":"89","author":"Rudnick","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior","volume":"9","author":"Hysek","year":"2014","journal-title":"Soc. Cogn. Affect. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1556\/2054.2023.00231","article-title":"Psychedelic therapy as reality transformation: A phenomenological approach","volume":"7","year":"2023","journal-title":"J. Psychedelic Stud."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1038\/s41598-023-32649-7","article-title":"A whole-brain model of the neural entropy increase elicited by psychedelic drugs","volume":"13","author":"Herzog","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1038\/s41598-023-28111-3","article-title":"From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)","volume":"15","author":"Zeifman","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1021\/acschemneuro.1c00815","article-title":"5-HT2A SNPs alter the pharmacological signaling of potentially therapeutic psychedelics","volume":"13","author":"Schmitz","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rossi, G.N., Guerra, L.T., Baker, G.B., Dursun, S.M., Saiz, J.C., Hallak, J.E., and Dos Santos, R.G. (2022). Molecular pathways of the therapeutic effects of ayahuasca, a botanical psychedelic and potential rapid-acting antidepressant. Biomolecules, 12.","DOI":"10.3390\/biom12111618"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","article-title":"The neural basis of psychedelic action","volume":"25","author":"Kwan","year":"2022","journal-title":"Nat. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"111139","DOI":"10.1016\/j.pnpbp.2024.111139","article-title":"The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies","volume":"136","author":"Low","year":"2024","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.neubiorev.2019.12.006","article-title":"Neuropharmacological modulation of the aberrant bodily self through psychedelics","volume":"108","author":"Ho","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1353\/ken.2022.0022","article-title":"Psychedelic identity shift: A critical approach to set and setting","volume":"32","author":"Devenot","year":"2022","journal-title":"Kennedy Inst. Ethics J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1192\/bjp.bp.116.194738","article-title":"Psychedelics and the science of self-experience","volume":"210","author":"Nour","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/15294145.2022.2052163","article-title":"Seeing oneself through the eyes of another: A look at psychedelic insight","volume":"24","author":"Fischman","year":"2022","journal-title":"Neuropsychoanalysis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105570","DOI":"10.1016\/j.neubiorev.2024.105570","article-title":"Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition\/creativity, emotional processing and personality","volume":"158","author":"Solaja","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the potential of psychedelics for the treatment of PTSD","volume":"23","author":"Krediet","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/02698811221089034","article-title":"Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences","volume":"36","author":"Ruban","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ko, K., Knight, G., Rucker, J.J., and Cleare, A.J. (2022). Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.917199"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1570159X22666231027111147","article-title":"The psychedelic future of post-traumatic stress disorder treatment","volume":"22","author":"Zaretsky","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1300\/J189v05n01_03","article-title":"Relational therapy for trauma","volume":"5","author":"Banks","year":"2006","journal-title":"J. Trauma Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjp.12852","article-title":"On redescribing the indescribable: Trauma, psychoanalysis and psychedelic therapy","volume":"39","author":"Modlin","year":"2023","journal-title":"Br. J. Psychother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.004","article-title":"MDMA and PTSD treatment: \u201cPTSD: From novel pathophysiology to innovative therapeutics\u201d","volume":"649","author":"Sessa","year":"2017","journal-title":"Neurosci. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1192\/bjo.2023.535","article-title":"Psilocybin for treatment-resistant depression without psychedelic effects: Study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial","volume":"9","author":"Husain","year":"2023","journal-title":"BJPsych Open"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bathje, G.J., Majeski, E., and Kudowor, M. (2022). Psychedelic integration: An analysis of the concept and its practice. Front. Psychol., 13.","DOI":"10.3389\/fpsyg.2022.824077"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wolff, M., Evens, R., Mertens, L.J., Koslowski, M., Betzler, F., Gr\u00fcnder, G., and Jungaberle, H. (2020). Learning to let go: A cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front. Psychiatry, 11.","DOI":"10.3389\/fpsyt.2020.00005"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: Past, present, and future","volume":"42","author":"Goodwin","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104193","DOI":"10.1016\/j.ajp.2024.104193","article-title":"Psychoactive substances for the treatment of neuropsychiatric disorders","volume":"101","author":"Zhen","year":"2024","journal-title":"Asian J. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Bolstridge","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/s41598-024-53188-9","article-title":"Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: A qualitative study","volume":"14","author":"Breeksema","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/JCP.0000000000001608","article-title":"A critical appraisal of evidence on the efficacy and safety of serotonergic psychedelic drugs as emerging antidepressants: Mind the evidence gap","volume":"42","author":"Ledwos","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1556\/2054.2023.00243","article-title":"Association between mystical-type experiences under psychedelics and improvements in well-being or mental health\u2013A comprehensive review of the evidence","volume":"7","author":"Kangaslampi","year":"2023","journal-title":"J. Psychedelic Stud."},{"key":"ref_51","first-page":"12","article-title":"Posttraumatic stress disorder and comorbidity: Recognizing the many faces of PTSD","volume":"58","author":"Brady","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09540261.2021.1919062","article-title":"Psilocybin and MDMA for the treatment of trauma-related psychopathology","volume":"33","author":"Bird","year":"2021","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1176\/appi.focus.23021011","article-title":"MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"21","author":"Mitchell","year":"2023","journal-title":"Focus"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-021-06027-y","article-title":"Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: A systematic review","volume":"239","author":"Schimmers","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","article-title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress","volume":"30","author":"Ross","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e9305","DOI":"10.1002\/ccr3.9305","article-title":"Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report","volume":"12","author":"Federico","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zafar, R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M., Nutt, D.J., and Erritzoe, D. (2023). Psychedelic therapy in the treatment of addiction: The past, present and future. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1183740"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/7854_2022_327","article-title":"Classic psychedelics in addiction treatment: The case for psilocybin in tobacco smoking cessation","volume":"56","author":"Johnson","year":"2022","journal-title":"Disruptive Psychopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874473708666150107120011","article-title":"Psychedelics as medicines for substance abuse rehabilitation: Evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca","volume":"7","author":"Winkelman","year":"2014","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/08873267.1997.9986876","article-title":"Treating the whole person: A holistic approach to psychotherapy","volume":"25","author":"Sultanoff","year":"1997","journal-title":"Humanist. Psychol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0022167817711304","article-title":"Developing guidelines and competencies for the training of psychedelic therapists","volume":"57","author":"Phelps","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/02698811251338214","article-title":"Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review","volume":"39","author":"Estric","year":"2025","journal-title":"J. Psychopharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","article-title":"Current perspectives on psychedelic therapy: Use of serotonergic hallucinogens in clinical interventions","volume":"30","author":"Richards","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Phelps, J. (2019). Training psychedelic therapists. Advances in Psychedelic Medicine: State of the Art Therapeutic Applications, Praeger Books.","DOI":"10.5040\/9798400607196.ch-014"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., and Sabbagh, J. (2021). Psychedelic harm reduction and integration: A transtheoretical model for clinical practice. Front. Psychol., 12.","DOI":"10.3389\/fpsyg.2021.645246"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2945","DOI":"10.1002\/cpp.2945","article-title":"Therapeutic frameworks in integration sessions in substance-assisted psychotherapy: A systematised review","volume":"31","author":"Thal","year":"2024","journal-title":"Clin. Psychol. Psychother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","article-title":"Studying harms is key to improving psychedelic-assisted therapy\u2014Participants call for changes to research landscape","volume":"80","author":"McNamee","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1126\/science.adg1324","article-title":"Pressing regulatory challenges for psychedelic medicine","volume":"380","author":"McGuire","year":"2023","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/psymed.2022.0004","article-title":"Personal psychedelic use is common among a sample of psychedelic therapists: Implications for research and practice","volume":"1","author":"Aday","year":"2023","journal-title":"Psychedelic Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Phelps, J., and Henry, J. (2021). Foundations for training psychedelic therapists. Disruptive Psychopharmacology, Springer International Publishing.","DOI":"10.1007\/7854_2021_266"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/2054.2019.032","article-title":"Diversity, equity, and access in psychedelic medicine","volume":"4","author":"Williams","year":"2020","journal-title":"J. Psychedelic Stud."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"106086","DOI":"10.1016\/j.neubiorev.2025.106086","article-title":"The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis","volume":"172","author":"Romeo","year":"2025","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Marseille, E., Stauffer, C.S., and Agrawal, M. (2023). Group psychedelic therapy: Empirical estimates of cost-savings and improved access. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1293243"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Vi\u00f1a, S.M. (2025). The Relationships Between Healthcare Access, Gender, and Psychedelics and Their Effects on Distress. Healthcare, 13.","DOI":"10.3390\/healthcare13101158"},{"key":"ref_75","first-page":"131","article-title":"The corporadelic set and setting: On the consequences of psychedelic commodification","volume":"65","author":"Hartogsohn","year":"2023","journal-title":"Hist. Pharm. Pharm."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Brennan, W., Jackson, M.A., MacLean, K., and Ponterotto, J.G. (2021). A qualitative exploration of relational ethical challenges and practices in psychedelic healing. J. Humanist. Psychol., 00221678211045265.","DOI":"10.1177\/00221678211045265"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/138920010794233495","article-title":"Psychedelic 5-methoxy-N, N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions","volume":"11","author":"Shen","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ray, T.S. (2010). Psychedelics and the human receptorome. PLoS ONE, 5.","DOI":"10.1371\/annotation\/e580a864-cf13-40c2-9bd9-b9687a6f0fe4"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/brain\/awab406","article-title":"Models of psychedelic drug action: Modulation of cortical-subcortical circuits","volume":"145","author":"Doss","year":"2022","journal-title":"Brain"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance","volume":"49","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Schmitz, G.P., Chiu, Y.T., K\u00f6nig, G.M., Kostenis, E., Roth, B.L., and Herman, M.A. (2022). Psychedelic compounds directly excite 5-HT2A layer 5 pyramidal neurons in the prefrontal cortex through a 5-HT2A Gq-mediated activation mechanism. BioRxiv.","DOI":"10.1101\/2022.11.15.516655"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Erritzoe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s002130050585","article-title":"Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors","volume":"136","author":"Egan","year":"1998","journal-title":"Psychopharmacology"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Nichols, D.E. (2022). Entactogens: How the name for a novel class of psychoactive agents originated. Front. Psychiatry, 13.","DOI":"10.3389\/fpsyt.2022.863088"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-021-03769-9","article-title":"Structural basis of ketamine action on human NMDA receptors","volume":"596","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Meshkat, S., Al-Shamali, H., Perivolaris, A., Tullu, T., Zeifman, R.J., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A., and Husain, M.I. (2025). Pharmacokinetics of Psilocybin: A Systematic Review. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17040411"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/03602532.2019.1638931","article-title":"Metabolism of lysergic acid diethylamide (LSD): An update","volume":"51","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","article-title":"Human pharmacology of MDMA: Pharmacokinetics, metabolism, and disposition","volume":"26","author":"Roset","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"De La Torre, R., Yubero-Lahoz, S., Pardo-Lozano, R., and Farr\u00e9, M. (2012). MDMA, methamphetamine, and CYP2D6 pharmacogenetics: What is clinically relevant?. Front. Genet., 3.","DOI":"10.3389\/fgene.2012.00235"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/17425250903505108","article-title":"Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression","volume":"6","author":"Chen","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Calina, D., Carvalho, F., and Docea, A.O. (2021). Toxicity of psychedelic drugs. Toxicological Risk Assessment and Multi-System Health Impacts from Exposure, Academic Press.","DOI":"10.1016\/B978-0-323-85215-9.00022-2"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s44161-025-00608-2","article-title":"Cardiovascular effects and safety of classic psychedelics","volume":"4","author":"Nahlawi","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: From anecdotes and misinformation to systematic science","volume":"36","author":"Schlag","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/S0140-6736(00)02276-5","article-title":"MDMA (Ecstasy) neurotoxicity: Assessing and communicating the risks","volume":"355","author":"Boot","year":"2000","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamapsychiatry.2022.0665","article-title":"Toward risk-benefit assessments in psychedelic-and MDMA-assisted therapies","volume":"79","author":"Bradberry","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: A review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Haijen, E.C., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R.E., Hampshire, A.D., and Lorenz, R. (2018). Predicting responses to psychedelics: A prospective study. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00897"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/02698811231211219","article-title":"Drug\u2013drug interactions involving classic psychedelics: A systematic review","volume":"38","author":"Halman","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"ref_100","first-page":"69","article-title":"Therapeutic guidelines: Dangers and contra-indications in therapeutic applications of hallucinogens","volume":"1","author":"Frecska","year":"2007","journal-title":"Psychedelic Med."},{"key":"ref_101","unstructured":"Fadiman, J. (2011). The Psychedelic Explorer\u2019s Guide: Safe, Therapeutic, and Sacred Journeys, Simon and Schuster."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0140-6736(23)00264-7","article-title":"The therapeutic potential of psychedelics: The European regulatory perspective","volume":"401","author":"Drummond","year":"2023","journal-title":"Lancet"},{"key":"ref_103","first-page":"464","article-title":"A brief historical overview of psychedelic research","volume":"9","author":"Geyer","year":"2024","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1556\/2054.2019.015","article-title":"The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion","volume":"4","author":"George","year":"2020","journal-title":"J. Psychedelic Stud."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/anoc.12161","article-title":"Indigenous Philosophies and the\u201d Psychedelic Renaissance\u201d","volume":"33","author":"Williams","year":"2022","journal-title":"Anthropol. Conscious."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1556\/2054.2019.031","article-title":"The role of Indigenous knowledges in psychedelic science","volume":"4","author":"Fotiou","year":"2020","journal-title":"J. Psychedelic Stud."},{"key":"ref_107","unstructured":"Kramer, N. (2022). The Efficacy of Relationality in a Psychedelic Community Healing Ritual: A Research-as-Ceremony Inquiry. [Doctoral Dissertation, Pacifica Graduate Institute]."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biopsych.2005.06.038","article-title":"Psychological and cognitive effects of long-term peyote use among Native Americans","volume":"58","author":"Halpern","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_109","unstructured":"Liu, Y.-F., and Wei, L.C. (2025). Advancing the Anthropology of Psychedelics: Integrating Clinical Evidence, Sociocultural Insights, and Ethical Frameworks. Anthropol. Conscious., e70004."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Dumit, J., and Sanabria, E. (2022). Set, setting, and clinical trials: Colonial technologies and psychedelics: Experiment. The Palgrave Handbook of the Anthropology of Technology, Springer Nature.","DOI":"10.1007\/978-981-16-7084-8_15"},{"key":"ref_111","first-page":"100410","article-title":"Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice","volume":"18","author":"Celidwen","year":"2023","journal-title":"Lancet Reg. Health\u2013Am."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"104507","DOI":"10.1016\/j.drugpo.2024.104507","article-title":"The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world","volume":"130","author":"Lake","year":"2024","journal-title":"Int. J. Drug Policy"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"20503245241235100","DOI":"10.1177\/20503245241235100","article-title":"Participation in an indigenous Amazonian-led ayahuasca retreat associated with increases in nature relatedness\u2013a pilot study","volume":"10","author":"Ruffell","year":"2024","journal-title":"Drug Sci. Policy Law"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/1467-8322.12813","article-title":"The making of a mushroom people: Toward a moral anthropology of psychedelics beyond hype and anti-hype","volume":"39","author":"Langlitz","year":"2023","journal-title":"Anthropol. Today"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/13634615211036388","article-title":"The socialization of hallucinations: Cultural priors, social interactions, and contextual factors in the use of psychedelics","volume":"59","author":"Dupuis","year":"2022","journal-title":"Transcult. Psychiatry"},{"key":"ref_116","first-page":"74","article-title":"Drug addictions, hallucinogens and shamanism: The view from anthropology","volume":"1","author":"Batchelder","year":"2001","journal-title":"Townsend Lett. Dr. Patients"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Soylemez, K.K., de Boo, E.M., and Lusher, J. (2025). Regulatory challenges of integrating psychedelics into mental health sector. Psychoactives, 4.","DOI":"10.3390\/psychoactives4020011"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.addicn.2022.100025","article-title":"Classic and non-classic psychedelics for substance use disorder: A review of their historic, past and current research","volume":"3","author":"Mendes","year":"2022","journal-title":"Addict. Neurosci."},{"key":"ref_119","unstructured":"Romero, O.S. (2022). Decolonizing the philosophy of psychedelics. Philosophy and Psychedelics: Frameworks for Exceptional Experience, Bloomsbury Publishing."},{"key":"ref_120","first-page":"1","article-title":"States and traits related to the quality and consequences of psychedelic experiences","volume":"6","author":"Russ","year":"2019","journal-title":"Psychol. Conscious. Theory Res. Pract."},{"key":"ref_121","unstructured":"D\u2019Angelo, E. (2025, May 01). The Choreography of the Soul: A Psychedelic Philosophy of Consciousness. Available online: https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/philarchive.org\/archive\/DANTCO-19&ved=2ahUKEwiO1anjudWPAxXVT2wGHenvA1gQFnoECBYQAQ&usg=AOvVaw2XU6NySccqo5HBNXLQ5bNa."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"0495","DOI":"10.34133\/research.0495","article-title":"Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy","volume":"7","author":"Zhang","year":"2024","journal-title":"Research"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_124","first-page":"1","article-title":"Dissolving the self: Active inference, psychedelics, and ego-dissolution","volume":"1","author":"Deane","year":"2020","journal-title":"Philos. Mind Sci."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Nour, M.M., Evans, L., Nutt, D., and Carhart-Harris, R.L. (2016). Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Front. Hum. Neurosci., 10.","DOI":"10.3389\/fnhum.2016.00269"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Martial, C., Fontaine, G., Gosseries, O., Carhart-Harris, R., Timmermann, C., Laureys, S., and Cassol, H. (2021). Losing the self in near-death experiences: The experience of ego-dissolution. Brain Sci., 11.","DOI":"10.3390\/brainsci11070929"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/johc.12164","article-title":"Psychedelics, mystical experiences, and meaning making: A renegotiation process with the challenges of existence","volume":"60","author":"Hearn","year":"2021","journal-title":"J. Humanist. Couns."},{"key":"ref_128","unstructured":"Sarmiento, N. (2025, May 01). Can Psychedelics Help Heal Trauma?. Available online: https:\/\/www.mirabilishealth.co.uk\/learn\/can-psychedelics-help-heal-trauma."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"van der Braak, A. (2025). The study of mystical experiences and Latour\u2019s ontological turn: Toward a participatory approach. Philos. Psychol., 1\u201327.","DOI":"10.1080\/09515089.2025.2506542"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2307\/2940818","article-title":"Materialism, reduction, replacement, and the place of consciousness in science","volume":"92","author":"Foss","year":"1995","journal-title":"J. Philos."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1556\/2054.2020.00136","article-title":"Tripping over the other: Could psychedelics increase empathy?","volume":"4","author":"Blatchford","year":"2021","journal-title":"J. Psychedelic Stud."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Chopra, S., and Letheby, C. (2024). Psychedelics and moral psychology: The case of forgiveness. Philosophical Perspectives on Psychedelic Psychiatry, Oxford Academic.","DOI":"10.1093\/oso\/9780192898371.003.0010"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Tijhuis, F.B., Coninx, S., and de Bruin, L.C. (2024). Existential feelings as a phenomenological framework for psychedelic therapy. Philos. Psychol., 1\u201329.","DOI":"10.1080\/09515089.2024.2412195"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/jpm.2017.0684","article-title":"Taking psychedelics seriously","volume":"21","author":"Byock","year":"2018","journal-title":"J. Palliat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Metzner, R. (2005). Psychedelic, psychoactive, and addictive drugs and states of consciousness. Mind-Altering Drugs: The Science of Subjective Experience, Oxford Academic.","DOI":"10.1037\/e719322011-027"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00213-022-06153-1","article-title":"Do psychedelics change beliefs?","volume":"239","author":"McGovern","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: Where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/rapm-2020-101273","article-title":"Chronic pain and psychedelics: A review and proposed mechanism of action","volume":"45","author":"Castellanos","year":"2020","journal-title":"Reg. Anesth. Pain Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/7854_2021_278","article-title":"The potential of psychedelics for end of life and palliative care","volume":"56","author":"Yaden","year":"2021","journal-title":"Disruptive Psychopharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Gold, V. (2023). A somatic approach to psychedelic-assisted therapy. Integral Psychedelic Therapy, Routledge.","DOI":"10.4324\/9781003167976-6"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Swanson, L.R. (2018). Unifying theories of psychedelic drug effects. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00172"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/papr.13203","article-title":"Are psychedelics the answer to chronic pain: A review of current literature","volume":"23","author":"Kooijman","year":"2023","journal-title":"Pain Pract."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pneurobio.2008.09.018","article-title":"Towards a theory of chronic pain","volume":"87","author":"Apkarian","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/JPR.S439348","article-title":"Scoping review: The role of psychedelics in the management of chronic pain","volume":"17","author":"Robinson","year":"2024","journal-title":"J. Pain Res."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Bornemann, J., Close, J.B., Spriggs, M.J., Carhart-Harris, R., and Roseman, L. (2021). Self-medication for chronic pain using classic psychedelics: A qualitative investigation to inform future research. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.735427"},{"key":"ref_147","unstructured":"Buurma, B. (2021). Psychedelics & Palliative Care: A Comparative Analysis of Institutional Logics. [Master\u2019s Thesis, Utrecht University Student]."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"109174","DOI":"10.1016\/j.neuropharm.2022.109174","article-title":"Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care","volume":"216","author":"Ross","year":"2022","journal-title":"Neuropharmacology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12152-024-09564-3","article-title":"How Do Psychedelics Reduce Fear of Death?","volume":"17","author":"Letheby","year":"2024","journal-title":"Neuroethics"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41386-022-01424-z","article-title":"Does the trip matter? Investigating the role of the subjective effects of psychedelics in persisting therapeutic effects","volume":"48","author":"Nautiyal","year":"2023","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ps.20220525","article-title":"Ethical and practical considerations for the use of psychedelics in psychiatry","volume":"74","author":"Barber","year":"2023","journal-title":"Psychiatr. Serv."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/07067437231225937","article-title":"Informed consent to psychedelic-assisted psychotherapy: Ethical considerations","volume":"69","author":"Lee","year":"2024","journal-title":"Can. J. Psychiatry"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/7854_2021_298","article-title":"Effects of setting on psychedelic experiences, therapies, and outcomes: A rapid scoping review of the literature","volume":"56","author":"Golden","year":"2022","journal-title":"Disruptive Psychopharmacol."},{"key":"ref_154","unstructured":"Noble, S. (2019). Statement: Public Announcement of Ethical Violation by Former MAPS-Sponsored Investigators, Multidisciplinary Association for Psychedelic Studies."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/psymed.2023.0028","article-title":"A systematic review of study design and placebo controls in psychedelic research","volume":"2","author":"Wen","year":"2024","journal-title":"Psychedelic Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"pyaf023","DOI":"10.1093\/ijnp\/pyaf023","article-title":"Addressing blinding in classic psychedelic studies with innovative active placebos","volume":"28","author":"Aday","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"26372","DOI":"10.1007\/s12144-024-06272-2","article-title":"Psychedelic experiences and long-term spiritual growth: A systematic review","volume":"43","author":"Schutt","year":"2024","journal-title":"Current Psychology."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Mosurinjohn, S., Roseman, L., and Girn, M. (2023). Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1077311"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/psymed.2023.0013","article-title":"Psychedelic commercialization: A wide-spanning overview of the emerging psychedelic industry","volume":"1","author":"Aday","year":"2023","journal-title":"Psychedelic Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1002\/fhu2.70004","article-title":"The Birth of the Psychedelic Industry: Capitalising on the Psychedelic Renaissance","volume":"3","author":"Yoo","year":"2025","journal-title":"Future Humanit."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/10\/450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:18:09Z","timestamp":1759151889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/10\/450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,28]]},"references-count":163,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jpm15100450"],"URL":"https:\/\/doi.org\/10.3390\/jpm15100450","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,28]]}}}